Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance

ACADIA PHARMACEUTICALS INC

2026-Q1 EPS reported $0.02 revenue$268,062,000

Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).
DAYBUE STIX launch underway; ~30% of STIX patients treatment-naive or returning after liquid discontinuation.
Phase 2 remlifanserin topline data in Alzheimer's disease psychosis expected Aug–Oct 2026, on track.
Trofinetide Japan trial results anticipated Sep–Nov 2026; Delphi panel recommends DAYBUE as Rett syndrome standard of care.
Reaffirms full-year 2026 financial guidance (no specific numbers provided).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ACADIA PHARMACEUTICALS INC reported the first quarter ended March 31, 2026 results: revenue total revenues of $268 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: total revenues of $268 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-209253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.